Mesopancreas dissection level 3 for pancreatic head cancer in combined robotic/open pancreatoduodenectomy: a propensity score-matched study
Surgical Endoscopy · 2025
DOI: 10.1007/s00464-024-11475-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgical Endoscopy, 2025. Verfasst von Bor-Shiuan Shyr und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Surgery, Department of Surgery and Therapeutic and Research Center of Pancreatic Cancer, Taipei Veterans General Hospital, Taipei…. Hauptthemen laut MEDLINE: Pancreaticoduodenectomy, Pancreatic Neoplasms, Robotic Surgical Procedures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: aipei Veterans General Hospital, Taipei Veterans General Hospital, Ministry of Science and Technology.
Abstract (Originalsprache)
Background
Mesopancreas dissection (MPD) level 3 in combined robotic/open pancreatoduodenectomy (CR/OPD) is technique-demanding. This study aims to clarify the feasibility and justification of MPD level 3.
Methods
Propensity score matching (PSM) analysis was conducted for 208 patients with pancreatic head cancer undergoing CR/OPD with or without MPD level 3. The comparison focused on surgical and oncological outcomes.
Results
After PSM, each group comprised 86 patients. Surgical outcomes were comparable between these two groups, except longer operation time for MPD level 3 (+), median: 10.5 vs. 9.5 h, p = 0.002. MPD level 3 (+) group exhibited higher lymph node yield, median: 20 vs. 17, p < 0.001, and curative (R0) resection rate, 89.5% vs. 69.8%, p = 0.001, compared to MPD level 3 (−) group. Among the entire cohort, no significant survival difference was observed between the MPD Level 3 (+) and (−) groups. Survival outcome for R0 resection after CR/OPD was notably better than those for R2 resection, 5-year survival: 34.0% vs. 0, p = 0.038. However, within the curative (R0) resection cohort, no survival difference was observed between the MPD level 3 (+) and MPD level 3 (−) groups.
Conclusion
MPD level 3 in CR/OPD is technically feasible without increasing the surgical risks but takes one hour extra operating time. Incorporation of MPD level 3 does not confer a survival advantage within the curative (R0) resection cohort. The primary focus should continue to be on achieving curative (R0) resection to maximize the survival benefits for pancreatic head cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of General Surgery, Department of Surgery and Therapeutic and Research Center of Pancreatic Cancer, Taipei Veterans General Hospital, Taipei Veterans General Hospital, National Yang Ming University, 201 Section…
- National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
- National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC. punkid830@gmail.com.
ORCID-Profile: Bor-Uei Shyr
Förderung
- aipei Veterans General Hospital
- Taipei Veterans General Hospital
- Ministry of Science and Technology
- Health Promotion Administration, Ministry of Health and Welfare
- National Yang Ming Chiao Tung University
Zitieren
APA
Shyr, B. S., Wang, S. E., Chen, S. C., Shyr, Y. M., & Shyr, B. U. (2025). Mesopancreas dissection level 3 for pancreatic head cancer in combined robotic/open pancreatoduodenectomy: a propensity score-matched study. Surgical Endoscopy. https://doi.org/10.1007/s00464-024-11475-6
Vancouver
Shyr BS, Wang SE, Chen SC, Shyr YM, Shyr BU. Mesopancreas dissection level 3 for pancreatic head cancer in combined robotic/open pancreatoduodenectomy: a propensity score-matched study. Surgical Endoscopy. 2025. doi:10.1007/s00464-024-11475-6
BibTeX
@article{Shyr2025,
author = {Shyr, Bor-Shiuan and Wang, Shin-E and Chen, Shih-Chin and Shyr, Yi-Ming and Shyr, Bor-Uei},
title = {Mesopancreas dissection level 3 for pancreatic head cancer in combined robotic/open pancreatoduodenectomy: a propensity score-matched study},
journal = {Surgical Endoscopy},
year = {2025},
doi = {10.1007/s00464-024-11475-6}
}
EUVIMED